Author: digi

SOP for IP Reconciliation and Accountability Logs

August 23, 2025

SOP for IP Reconciliation and Accountability Logs { “@context”: “https://schema.org”, “@type”: “Article”, “mainEntityOfPage”: { “@type”: “WebPage”, “@id”: “https://www.Clinicalstudies.in/SOP-for-IP-Reconciliation-and-Accountability-Logs” }, “headline”: “SOP for IP Reconciliation and Accountability Logs in Clinical Trials”, “description”: “This SOP outlines standardized procedures for reconciliation and accountability of investigational products (IP) in clinical trials, ensuring accurate documentation and compliance with ICH GCP,…

Global SOPs (Applicable to all Agencies), SOP for GCP

Use of Technology in Age-Specific Recruitment

August 23, 2025

digi

Use of Technology in Age-Specific Recruitment Using Technology to Recruit Children and Older Adults—Without Losing Trust Why Age-Specific Technology Matters in Recruitment Digital tools can widen access to clinical trials, but one size never fits all—especially across pediatrics and geriatrics. Caregivers, teens, and older adults interact with technology differently. The same Instagram post that reaches…

Pediatric and Geriatric Clinical Trials, Recruitment Strategies

Inadequate Investigator Knowledge Reported in Clinical Trial Audits

August 23, 2025

digi

Inadequate Investigator Knowledge Reported in Clinical Trial Audits Why Inadequate Investigator Knowledge Leads to Audit Findings Introduction: Investigator Knowledge as a Pillar of GCP Compliance Clinical investigators play a central role in safeguarding participant safety and ensuring trial credibility. Regulators including the FDA, EMA, and MHRA emphasize that investigators must demonstrate adequate knowledge of the…

GCP Training & Compliance Audit Findings, Regulatory Audit Findings

Mobile App Solutions for Rare Disease Trial Data Capture

August 22, 2025

digi

Mobile App Solutions for Rare Disease Trial Data Capture Transforming Rare Disease Clinical Trials with Mobile Data Capture Solutions The Need for Mobile Data Capture in Rare Disease Trials Rare disease clinical trials face multiple operational hurdles, from small sample sizes to geographically dispersed participants. Traditional data collection methods such as paper diaries or in-clinic…

Data & Technology, Rare and Orphan Disease Trials

Chain of Custody in Clinical Trial Logistics

August 22, 2025

digi

Chain of Custody in Clinical Trial Logistics Ensuring Chain of Custody in Clinical Trial Logistics Introduction: Why Chain of Custody Matters Chain of custody (CoC) refers to the documented and unbroken trail showing the movement and handling of investigational medicinal products (IMPs) from manufacturer to depot, site, and ultimately the patient. For US sponsors, the…

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Overcoming Randomization Limitations in Ultra-Rare Disease Studies

August 22, 2025

digi

Overcoming Randomization Limitations in Ultra-Rare Disease Studies Innovative Strategies to Address Randomization Challenges in Ultra-Rare Disease Trials Understanding the Randomization Barrier in Ultra-Rare Disease Research Randomization is a fundamental principle in clinical trial design, intended to reduce bias and ensure balanced comparison groups. However, in the context of ultra-rare diseases—conditions affecting fewer than one in…

Rare and Orphan Disease Trials, Trial Design & Methodology

Templates and Tools for RBM Plan Development

August 22, 2025

digi

Templates and Tools for RBM Plan Development Essential Templates and Tools to Build a Strong RBM Monitoring Plan Introduction: Why Tools and Templates Are Vital in RBM Planning Risk-Based Monitoring (RBM) has become the preferred strategy for efficient, compliant clinical trial oversight. However, the complexity of developing a robust RBM plan—one that aligns with ICH…

Monitoring Plan Development, Risk-Based Monitoring (RBM)

What to Include in a Biologics License Application (BLA)

August 22, 2025

digi

What to Include in a Biologics License Application (BLA) Detailed Guide to Preparing a Biologics License Application (BLA) Introduction: The Importance of a Well-Structured BLA A Biologics License Application (BLA) is the critical regulatory submission that allows a sponsor to market a biologic product in the United States. Unlike NDAs (New Drug Applications), which cover…

NDA/BLA/MAA Filings, Regulatory Submissions and Approvals

Integrating Registry Posting with Clinical Study Report Development

August 22, 2025

digi

Integrating Registry Posting with Clinical Study Report Development How to Align CSR Development with Clinical Trial Registry Posting Why Integration of CSR and Registry Posting is Crucial The Clinical Study Report (CSR) and registry result postings serve different regulatory purposes but originate from the same clinical dataset. The CSR, structured according to ICH E3 guidelines,…

Clinical Trial Registries and Result Disclosure, Results Posting Requirements

Documentation Requirements for RCA Reports

August 22, 2025

digi

Documentation Requirements for RCA Reports How to Document Root Cause Analysis Reports for Regulatory Compliance The Critical Role of RCA Documentation in Clinical Trials Root Cause Analysis (RCA) is a key requirement under ICH-GCP guidelines for investigating protocol deviations, adverse events, and non-compliance in clinical trials. However, it’s not enough to simply conduct an RCA—the…

Protocol Deviation and CAPA Management, Root Cause Analysis